New drug hope for rare heart condition: baricitinib trial launches
NCT ID NCT06868381
First seen Feb 19, 2026 · Last updated Apr 28, 2026 · Updated 4 times
Summary
This early-stage trial tests whether baricitinib, taken with a steroid-sparing medication, can reduce heart inflammation in adults with cardiac sarcoidosis. Ten participants will take the drug for 16 weeks and have regular PET scans to see if inflammation improves. The goal is to find a better treatment option for this rare condition.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CARDIAC SARCOIDOSIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Email: •••••@•••••
Locations
-
Stanford University
Palo Alto, California, 94304-2210, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.